ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 581,66
-0,67%
Dow Jones
40 211,72
0,53%
DAX
18 504,69
-0,51%
Brent Oil
83,665
-0,80%
Bitcoin
63 216,88
-2,52%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NYSE
  6. Teva Pharmaceutical Industries Ltd (TEVA)

  7. Teva Pharmaceutical Industries Ltd (TEVA) Actualités

TEVA

Teva Pharmaceutical Indu... (TEVA)

Teva Pharmaceutical Industries Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:TEVA
DateHeureSourceTitreSymboleSociété
27/09/201821h00Business WireTeva Announces Exclusive First-to-File Launch of a Generic Version of Cialis® in the United StatesNYSE:TEVATeva Pharmaceutical Industries Ltd
20/09/201822h14Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:TEVATeva Pharmaceutical Industries Ltd
18/09/201813h00Business WireTeva Announces Early Results of Debt Tender Offer and Election of Early SettlementNYSE:TEVATeva Pharmaceutical Industries Ltd
15/09/201804h00Business WireADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First & Only Anti-CGRP Treatment...NYSE:TEVATeva Pharmaceutical Industries Ltd
15/09/201802h35Dow Jones NewsFDA Approves Teva's Migraine Drug Ajovy -- UpdateNYSE:TEVATeva Pharmaceutical Industries Ltd
15/09/201802h14Dow Jones NewsFDA Approves Teva's Migraine Drug AjovyNYSE:TEVATeva Pharmaceutical Industries Ltd
15/09/201800h48Business WireTeva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First & Only Anti-CGRP Treatment with Both Quarter...NYSE:TEVATeva Pharmaceutical Industries Ltd
12/09/201818h28Business WireTeva to Present at the Morgan Stanley Global Healthcare ConferenceNYSE:TEVATeva Pharmaceutical Industries Ltd
12/09/201809h15Dow Jones NewsIndivior: Sublocade Uptake Picking UpNYSE:TEVATeva Pharmaceutical Industries Ltd
10/09/201819h58Dow Jones NewsAcorda Shares Tumble After Court RulingNYSE:TEVATeva Pharmaceutical Industries Ltd
10/09/201818h41PR Newswire (Canada)Teva Canada annonce le lancement d'une version générique de (Pr)Abilify(MD) : les comprimés(Pr)Teva-Aripiprazole pour le t...NYSE:TEVATeva Pharmaceutical Industries Ltd
10/09/201818h10PR Newswire (Canada)Teva Canada Announces the Launch of a Generic Version of (PR)Abilify®, (PR)Teva-Aripiprazole Tablets for the treatment of Sc...NYSE:TEVATeva Pharmaceutical Industries Ltd
08/09/201800h09Dow Jones NewsFDA Approves TEVA's Cassipa to Treat Opioid DependenceNYSE:TEVATeva Pharmaceutical Industries Ltd
06/09/201822h05PR Newswire (US)Teva, NACHC and Direct Relief Provide Important Insights on Prescription Medicine Access for Underserved Patients at the AAM ...NYSE:TEVATeva Pharmaceutical Industries Ltd
04/09/201817h44Business WireTeva Announces $400 Million Debt Tender OfferNYSE:TEVATeva Pharmaceutical Industries Ltd
25/08/201815h29Dow Jones NewsEpiPen Shortage Hits Back-to-School SeasonNYSE:TEVATeva Pharmaceutical Industries Ltd
16/08/201823h54Dow Jones NewsAntares Pharma Shares Rise After FDA Approves First Rival Generic EpiPenNYSE:TEVATeva Pharmaceutical Industries Ltd
16/08/201814h06Dow Jones NewsRegeneron, Teva Report Positive Phase 3 Fasinumab ResultsNYSE:TEVATeva Pharmaceutical Industries Ltd
16/08/201813h00PR Newswire (US)Regeneron and Teva Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of t...NYSE:TEVATeva Pharmaceutical Industries Ltd
16/08/201813h00Business WireTeva & Regeneron Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the...NYSE:TEVATeva Pharmaceutical Industries Ltd
06/08/201814h00Business WireTeva Announces Updated Indication and Vial Presentation for GRANIX® (tbo-filgrastim) Injection in United StatesNYSE:TEVATeva Pharmaceutical Industries Ltd
03/08/201815h39Dow Jones NewsAcorda Signs Settlement With Mylan on Generic AmpyraNYSE:TEVATeva Pharmaceutical Industries Ltd
02/08/201819h16Dow Jones NewsTeva Pharmaceutical's Sales Slump 18%NYSE:TEVATeva Pharmaceutical Industries Ltd
02/08/201813h00Business WireTeva Reports Second Quarter 2018 Financial ResultsNYSE:TEVATeva Pharmaceutical Industries Ltd
25/07/201820h36Dow Jones NewsAcorda Shares Fall as Court Denies Injunction Request in Patent Case -- Market MoverNYSE:TEVATeva Pharmaceutical Industries Ltd
17/07/201814h30Business WireTeva Highlights Key Milestones Achieved in the 2017 Social Impact ReportNYSE:TEVATeva Pharmaceutical Industries Ltd
14/07/201802h05Dow Jones NewsFDA Recalls Several Medicines That Contain ValsartanNYSE:TEVATeva Pharmaceutical Industries Ltd
11/07/201814h00Business WireTeva to Report Second Quarter 2018 Financial Results on August 2, 2018NYSE:TEVATeva Pharmaceutical Industries Ltd
09/07/201816h47Business WireTeva Announces Launch of a Generic Version of Uceris® in the United StatesNYSE:TEVATeva Pharmaceutical Industries Ltd
28/06/201823h06Dow Jones NewsADRs End HigherNYSE:TEVATeva Pharmaceutical Industries Ltd
 Showing the most relevant articles for your search:NYSE:TEVA

Dernières Valeurs Consultées

EU
AI
Air Liquide
NASDAQ
AAPL
Apple
EU
PX1
CAC 40
EU
VIV
Vivendi
EU
BNP
BNP Paribas
NASDAQ
GOOGL
Alphabet
FTSE
UKX
FTSE 100
COIN
BTCUSD
Bitcoin
NYSE
NKE
Nike
EU
HO
Thales
EU
AF
Air FranceKLM
EU
PX4
SBF 120
EU
EN
Bouygues
EU
MC
Lvmh Moet Hennessy Louis...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés